Evaluation of the Effectiveness of PREVENIR (PREVention ENvIronnement Reproduction) Platforms
Launched by UNIVERSITY HOSPITAL, BORDEAUX · Oct 14, 2024
Trial Information
Current as of July 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The clinical trial titled "Evaluation of the Effectiveness of PREVENIR Platforms" aims to study how certain interventions can help pregnant women reduce their exposure to environmental factors, specifically measuring levels of phenoxyacetic acid in their urine. This research will compare two groups of women: one group will receive the intervention while the other will not. By looking at urine samples taken at the start of the study and three months later, researchers hope to see if the intervention makes a difference in reducing these harmful levels.
To be eligible for this study, women must be pregnant and less than 24 weeks along, and they should be over 18 years old. The trial will include all women regardless of their background. Participants can expect to be part of a study that could lead to better health outcomes for mothers and their babies by understanding how to manage environmental exposures during pregnancy. It’s important to note that this trial is not yet recruiting participants, and anyone who is interested should keep an eye out for updates on when enrollment begins.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All pregnant women less than 24 SA of age referred to the PREVENIR platforms participating in the study for management.
- • Only women less than 24 SA months pregnant will be included to limit the number of women who gave birth during the study.
- • More than 18 years old
- For qualitative study:
- • Professionnal working within PREVENIR platforms
- • Women included in the intervention group and who agreed with participating
- Exclusion Criteria:
- • Women under court protection, under guardianship or curatorship, severely altered physical and/or psychological health, which, in the opinion of the investigator, may affect the participant's compliance to the study.
- • Women with an altered medical condition related to prgnancy that may required a therapeutic abortion according to the environmental expert
- • Non-French speakers
About University Hospital, Bordeaux
The University Hospital of Bordeaux is a leading academic medical center dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the institution integrates cutting-edge scientific inquiry with patient care, fostering an environment that encourages collaboration among multidisciplinary teams. With a commitment to improving treatment outcomes and enhancing patient safety, the University Hospital of Bordeaux plays a pivotal role in the development of new therapies and medical technologies, contributing significantly to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Fleur DELVA, MD
Principal Investigator
University Hospital, Bordeaux
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported